FDA Grants Accelerated Approval to Tecentriq-Abraxane Combo for Some TNBC

FDA Grants Accelerated Approval to Tecentriq-Abraxane Combo for Some TNBC
The U.S. Food and Drug Administration has granted accelerated approval to a combination of Tecentriq (atezolizumab) and the chemotherapy Abraxane (nab-paclitaxel) for patients with advanced triple-negative breast cancer, making this the first immunotherapy regimen approved specifically for breast cancer. The approval, which is for patients whose tumors produce the PD-L1 factor and are unable to receive surgery, was based on data from the IMpassion130 Phase 3 trial (NCT02425891), where the combination cut the risk of death or disease worsening by 40% compared to Abraxane only. Continued approval of this Tecentriq combination, like most accelerated approvals, is contingent on additional data confirming that the approach also brings overall survival benefits. The agency also approved the Ventana PD-L1 Assay as a companion diagnostic device for selecting triple-negative breast cancer eligible for the combination treatment. “The FDA approval of this Tecentriq combination is an important treatment advance for people with PD-L1-positive, metastatic triple-negative breast cancer, a disease with high unmet medical need,” Sandra Horning, MD, chief medical officer and head of global pr
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.